KLK3 and prostate carcinoma: Current prostate cancer diagnostic pathways still hinge on serum PSA prompting targeted or systematic biopsy, although PSA’s limited specificity and frequent benign or inflammatory elevations drive avoidable procedures and overdiagnosis [1].